

Quarterly Activities Report for the period ending 31 March 2026

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 31 March 2026 (Q3 FY2026), together with its Appendix 4C Quarterly Cash Flow Report.

HIGHLIGHTS

- First clinical site initiated and open for recruitment in Phase 3 “Beyond Harmony” trial, evaluating NTI164 in paediatric patients with Autism Spectrum Disorder
- 90-day GLP toxicology study among non-rodents shows NTI164 to be well tolerated with no mortality or dose-limiting toxicities
- PANS clinical & mechanistic data for NTI164 published in leading scientific journal *Neurotherapeutics*
- Neurotech has collaborated with The University of Sydney to advance the development NTI164 for Rett syndrome
- The Company continued significant PR/IR efforts during the period with coverage in the Herald Sun, while presenting at several roadshows & investor conferences

R&D UPDATES

First Clinical Site Initiated for Phase 3 “Beyond Harmony” Trial

In March, the Company initiated the first clinical site for its Phase 3 “Beyond Harmony” trial evaluating NTI164 in paediatric patients with Autism Spectrum Disorder (ASD), representing a significant milestone in Neurotech’s clinical development and an important step toward potential regulatory registration and potential commercialisation of NTI164.

The first site to be activated is Monash Children's Hospital, one of Australia's leading paediatric medical and research facilities. The site is now open for patient screening and recruitment following receipt of all required regulatory approvals.

One hundred and fifty patients are planned for enrolment under the adaptive trial design. The design permits pre-specified modifications based on interim analyses while maintaining scientific and regulatory integrity. The trial is appropriately statistically powered and conducted in accordance with applicable regulatory guidelines and requirements.

In advancing this pivotal Phase 3 program, the Company is working closely with a group of international clinical and regulatory experts to support study expansion, global alignment and execution of its broader development strategy. Additional clinical sites are expected to be initiated in the coming months as the study progresses.

The initiation of the first site occurred following the HREC approval to commence the Beyond Harmony Phase 3 study, received in February.

NTI164 demonstrates favourable long-term safety profile in GLP non-rodent study

During the quarter, the Company received positive results from a 90-day GLP repeat-dose oral toxicity study of its lead drug candidate NTI164, conducted in a non-rodent species (Beagle dogs).

The toxicology results demonstrated a favourable safety and tolerability profile across all dose levels tested, with no mortality or dose-limiting toxicities observed at any stage of the study. NTI164 was well tolerated at the highest administered dose of 216 mg/kg/day – representing approximately ten times the highest prescribed human dose evaluated to date in completed studies – administered twice daily over the 90-day period. There were no clinically meaningful adverse effects on body weight, food consumption, hematology, coagulation parameters, or general clinical observations throughout the dosing phase. Any treatment-related findings identified at higher dose levels were mild in nature and reversible, with full recovery observed following a 14-day non-dosing period. All animals completed the planned dosing schedule with no treatment-related early terminations, and no progressive, irreversible, or life-threatening toxicities were identified.

Following consultation with the US FDA through Type C and Type D meeting interactions, additional central nervous system-focused safety assessments were incorporated into the study, including enhanced brain sectioning and detailed analysis. These expanded evaluations did not identify any safety concerns, further supporting the favourable safety profile of NTI164.

The positive results support the long-term dosing potential of NTI164 and strengthen the Company's IND/TGA-enabling safety package, required to support further clinical and regulatory activities under US FDA and Australian TGA registration guidelines.

PANS Clinical & Mechanistic Data Published in Leading Scientific Journal

In January, Neurotech announced the publication of clinical and mechanistic data for its lead drug NTI164 in *Neurotherapeutics*, a leading peer-reviewed journal and the official journal of the American Society for Experimental NeuroTherapeutics. The publication reports results from a sub-cohort of patients enrolled in Neurotech's Phase I/II open-label clinical trial in Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), alongside a comprehensive multi-omics analysis examining immune and epigenetic pathways.

The study evaluated NTI164 administered orally at 20 mg/kg/day over 12 weeks in 14 children with chronic, relapsing PANS, a severe neuroimmune disorder with no approved treatments. NTI164 was well tolerated, with no serious adverse events and only mild, self-limiting side effects reported. Clinically, treatment led to statistically significant improvements across all major disease domains, including overall disease severity, anxiety, obsessive-compulsive symptoms, tics, ADHD symptoms and quality of life.

Importantly, the mechanistic analysis demonstrated that children with PANS exhibit widespread dysregulation of epigenetic, ribosomal and immune pathways, and that these same pathways were significantly normalised following NTI164 treatment. This included restoration of ribosomal and mitochondrial function and broad modulation of immune and inflammatory signalling, providing molecular evidence that supports the observed clinical improvements.

Publication of these data in a high-impact scientific journal further strengthens the scientific foundation of NTI164 and provides independent validation of its therapeutic potential across PANS and other neuroinflammatory paediatric indications, supporting Neurotech's broader clinical development strategy.

Neurotech collaborates with University of Sydney in Rett syndrome program

In February, Neurotech announced a research collaboration with The University of Sydney to advance the development of its proprietary cannabinoid-based compound NTI164 for Rett syndrome.

The program will be led by Professor Wendy Gold, interim Head of School of Medical Sciences at the University of Sydney's Faculty of Medicine and Health, who is an internationally recognised expert in human neuronal modelling of neurodevelopmental disorders including Rett syndrome. Preclinical observations to date suggest that NTI164 may exert potent, multi-modal activity across several key Rett-associated pathways, and the collaboration will focus on defining how NTI164 modulates fundamental disease mechanisms in this disease model. The research will utilise human derived Rett syndrome neuronal models, enabling direct investigation of disease-relevant cellular, molecular, and functional abnormalities associated with MECP2 deficiency.

This collaboration follows the successful completion of Neurotech's Phase 1 clinical study in Rett syndrome, with the company now expanding its program to further characterise the mechanism of action of NTI164 in human Rett disease models. Rett syndrome is described as a rare and severe neurodevelopmental disorder characterised by widespread disruption of gene regulation, mitochondrial dysfunction, impaired synaptic development, and abnormal neuronal network activity.

CORPORATE ACTIVITIES

Media coverage in Herald Sun

During March, Neurotech received outstanding media coverage with Melbourne-based newspaper Herald Sun reporting on NTI164 entering its Phase 3 clinical trial for children with autism, aiming to treat core symptoms of the condition. The article noted that early studies had shown promising improvements in mood, anxiety and cognitive engagement, and if successful, the therapy could become one of the first approved treatments globally for core autism symptoms.

[The article \(paywalled\) can be viewed at this link.](#)

Participation in Ignite Investment Summit Hong Kong

Subsequent to the end of the period, Neurotech CEO & Managing Director Dr Anthony Filippis participated in the Ignite Investment Summit held in Hong Kong.

The event saw Dr Filippis conduct numerous investor meetings as well as delivering a group presentation on Neurotech to those in attendance.

A copy of the presentation can be viewed via the Company's ASX announcement released on 13 April 2026.

Presentation at NWR Virtual Healthcare Conference

During March, Dr Filippis presented a Company update at the NWR Virtual Healthcare Conference.

A replay of the presentation is available at: https://youtu.be/P8_AdN3_OWw?si=gfvRIkoC2C1PDbKz

A copy of the presentation slides was previously released to ASX on 18 March 2026.

Corporate and business development

The Company continues to advance discussions with pharmaceutical and biotechnology partners and investors, including parties who have progressed to more detailed stages of evaluation; however, no binding or material agreements have been entered into at this time.

Neurotech US Medical Advisor Dr Bonni Goldstein appointed to National Compassionate Care Council¹

Subsequent to the end of the period, Neurotech's U.S. Medical Advisor Dr Bonni Goldstein was appointed to the newly formed National Compassionate Care Council ("Council"), focused on advancing U.S. medical cannabis policy, clinical practice, and patient access.

The Council will provide scientific and clinical guidance, develop frameworks and standards of care for therapeutic use, and promote real-world evidence to support dosing, safety, and efficacy. It will also bring together key stakeholders to improve access to safe, consistent, and equitable cannabinoid-based treatments.

Appendix 4C Commentary

During the quarter, the Company recorded total cash operating expenses (excluding revenue sources) of ~\$2.2 million (Q2 FY2026: \$3.4 million), consisting of research and development costs of ~\$2.0 million (Q2 FY2026: \$3.1 million), along with advertising, marketing, staff, administrative, and corporate costs of ~\$0.2 million (Q2 FY2026: \$0.3 million).

R&D expenditure during the quarter was primarily driven by continued investment in IND-enabling preclinical development and toxicology programs supporting regulatory submissions to both the FDA and TGA. Additional spending related to ongoing extension-phase activities within the Phase II/III ASD clinical program. Further R&D investment included maintenance and follow-up costs for participants transitioning into extension phases of prior clinical trials, alongside drug product manufacturing and process development, quality and stability programs, preclinical formulation work, and regulatory activities supporting current and planned submissions.

Total operating cash outflows for the quarter were ~\$2.2 million (Q2 FY2026: cash inflows of \$1.2 million).

The Company closed the quarter with cash and cash equivalents of ~\$4.3 million (Q2 FY26: \$6.3 million).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C totalled \$167,000.

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric

¹ Dr Goldstein's appointment is independent of her role with Neurotech. This update is provided for general background on the professional activities of members of Neurotech's advisory team and does not relate to the Company's operations or strategy.

Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Forward Looking Statements

This announcement includes forward-looking statements, including forward-looking statements relating to the future operation of the Company. These forward-looking statements are based on the Company's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to subsequently update or revise the forward-looking statements made in this announcement to reflect the circumstances or events after the date of this announcement. There is no guarantee that the ASD Phase 3 study will be successful or that NTI164 will receive regulatory approval. You are strongly cautioned not to place undue reliance on forward-looking statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Neurotech International Limited

ABN

73 610 205 402

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	0	0
1.2 Payments for		
(a) research and development	(2,018)	(6,032)
(b) product manufacturing and operating costs	0	0
(c) advertising and marketing	(40)	(155)
(d) leased assets	0	0
(e) staff costs	(117)	(313)
(f) administration and corporate costs	(80)	(493)
1.3 Dividends received (see note 3)	0	0
1.4 Interest received	13	20
1.5 Interest and other costs of finance paid	(2)	(5)
1.6 Income taxes paid	0	0
1.7 Government grants and tax incentives (R&D Rebate)	0	4,734
1.8 Other (GST refunds)	0	0
1.9 Net cash from / (used in) operating activities	(2,244)	(2,244)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	0	0
(b) businesses	0	0
(c) property, plant and equipment	0	0
(d) investments	0	0
(e) intellectual property	0	0

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	Net cash from / (used in) investing activities	0	0

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	300	3,754
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(18)	(164)
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	Net cash from / (used in) financing activities	282	3,590

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	6,340	3,032
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,244)	(2,244)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	282	3,590
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of period	4,378	4,378

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,863	6,325
5.2	Call deposits	2,515	15
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,378	6,340

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	167
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0
Payments at section 6. relate to director fees (\$41,000), executive salaries (\$117,000) and reimbursement (\$9,000).		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	67	0
7.2	Credit standby arrangements	0	0
7.3	Other (please specify)	0	0
7.4	Total financing facilities	67	0
7.5	Unused financing facilities available at quarter end		67
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. Overdraft facility with a limit of EUR 40,000. The lender is Bank of Valetta. The facility is unsecured. The interest rate is 5.65%. The above values are stated in AUD, converted from EUR at an exchange rate of 0.597.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	2,244
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,378
8.3	Unused finance facilities available at quarter end (item 7.5)	67
8.4	Total available funding (item 8.2 + item 8.3)	4,445
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.98
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? The Company expects a reduction in operating cash outflows in Q1 FY2027, reflecting the absence of significant expenditure on cultivation and preclinical activities during the quarter. The level of expenditure may fluctuate between quarters depending on timing of activities and will be managed in line with the Company's available funding.	

- 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

The Company continues to monitor its funding position and expenditure requirements closely. NTI expects to receive cash inflows from the R&D Tax Incentive of approximately \$3.5m in Q2 FY2027. The Company retains flexibility to consider funding initiatives as and when required and will manage its expenditure in line with available funding.

- 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes, refer to 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 April 2026

Authorised by: The Board of Directors

.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.